Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice-Reference-Cited by-同舟云学术

Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice

Published:2004-03 Issue:3 Volume:126 Page:886-894
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Fernandez Mercedes,Vizzutti Francesco,Garcia-Pagan Juan Carlos,Rodes Juan,Bosch Jaime

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Pathophysiology of portal hypertension;Bosch;Gastroenterol Clin North Am,1992

2. Blood vessel formation;Folkman;Cell,1996

3. Mechanisms of angiogenesis;Risau;Nature,1997

4. Monoclonal antibodies targeting the VEGF receptor-2 (Flk-1/KDR) as an anti-angiogenic therapeutic strategy;Witte;Cancer Metastasis Rev,1998

5. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors;Prewett;Cancer Res,1999

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduced risk of overt hepatic encephalopathy and death after transjugular intrahepatic portosystemic shunt in patients with hepatic venovenous communications;European Journal of Radiology;2024-08

2. Role of splenomegaly in surgical treatment of portal hypertension;World Chinese Journal of Digestology;2024-04-28

3. The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma;Expert Opinion on Therapeutic Targets;2024-03-03

4. Melatonin alleviated splanchnic hyperdynamic circulation and portosystemic collaterals in cirrhotic rats;Advances in Digestive Medicine;2024-02-25

5. Paneth cell: The missing link between obesity, MASH and portal hypertension;Clinics and Research in Hepatology and Gastroenterology;2024-01